Edwards Lifesciences Corporation
EW
$71.53
$0.330.46%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.44B | 5.32B | 5.21B | 5.12B | 5.01B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.44B | 5.32B | 5.21B | 5.12B | 5.01B |
| Cost of Revenue | 1.12B | 1.08B | 1.06B | 1.04B | 978.40M |
| Gross Profit | 4.32B | 4.24B | 4.15B | 4.08B | 4.03B |
| SG&A Expenses | 1.79B | 1.71B | 1.67B | 1.63B | 1.58B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -300.00K | -153.60M | -176.00M | -37.00M | 0.00 |
| Total Operating Expenses | 3.96B | 3.66B | 3.57B | 3.62B | 3.52B |
| Operating Income | 1.48B | 1.66B | 1.63B | 1.50B | 1.49B |
| Income Before Tax | 1.55B | 1.53B | 1.51B | 1.40B | 1.37B |
| Income Tax Expenses | 152.10M | 141.10M | 153.10M | 153.70M | 152.40M |
| Earnings from Continuing Operations | 1.40K | 1.38K | 1.36K | 1.24K | 1.22K |
| Earnings from Discontinued Operations | 2.77B | 2.77B | 112.50M | 165.40M | 179.40M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.90M | 3.80M | 3.60M | 3.90M | 3.00M |
| Net Income | 4.17B | 4.16B | 1.47B | 1.41B | 1.40B |
| EBIT | 1.48B | 1.66B | 1.63B | 1.50B | 1.49B |
| EBITDA | 1.64B | 1.81B | 1.79B | 1.65B | 1.63B |
| EPS Basic | 6.99 | 6.95 | 2.44 | 2.34 | 2.31 |
| Normalized Basic EPS | 1.68 | 1.84 | 1.78 | 1.64 | 1.60 |
| EPS Diluted | 6.98 | 6.94 | 2.43 | 2.33 | 2.30 |
| Normalized Diluted EPS | 1.67 | 1.84 | 1.77 | 1.63 | 1.60 |
| Average Basic Shares Outstanding | 2.39B | 2.41B | 2.42B | 2.42B | 2.43B |
| Average Diluted Shares Outstanding | 2.40B | 2.41B | 2.42B | 2.43B | 2.44B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |